Screener
Axsome Therapeutics AXSM CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating lease liability | (608) | 208 |
| Net cash used in operating activities | (20,700) | (43,375) |
| Cash flows from investing activities | ||
| Purchases of equipment | (121) | (338) |
| Net cash used in investing activities | (121) | (338) |
| Cash flows from financing activities | ||
| Proceeds from draw down of debt | 70,000 | — |
| Repayment of debt | (70,000) | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's capex?
- Axsome Therapeutics (AXSM) reported capex of $121K in Q1 2026.
- How has Axsome Therapeutics's capex changed year-over-year?
- Axsome Therapeutics's capex decreased by 64.2% year-over-year, from $338K to $121K.
- What is the long-term trend for Axsome Therapeutics's capex?
- Over 4 years (2021 to 2025), Axsome Therapeutics's capex has grown at a 11.7% compound annual growth rate (CAGR), from $308K to $480K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Axsome Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude